The technologies were developed by Hawaii Biotech and acquired by Merck in 2010.
Hawaii Biotech CEO Elliot Parks said the licenses would help in the development of vaccines for TBE, malaria, and other subunit vaccines for various infectious diseases.
"We are pleased with the working relationship we have established with Merck, appreciate their cooperation, and look forward to continuing the development of these vaccine candidates," Parks added.